An observational study in Aggressive Spinal Hemangiomas, sponsored by Assiut University. Not yet recruiting. Per ClinicalTrials.gov, last updated 2025-05-30.
Sponsored by Assiut University · Observational
This research is a case series analysis to evaluate aggressive vertebral hemangiomas. It focuses on clinical presentation, diagnostic imaging accuracy (X-ray, MRI, MSCT, angiography), and treatment efficacy. The primary goal is to establish optimal management protocols.
Hybrid methodology integrating retrospective case reviews (from Assiut University Hospital's Orthopedic Surgery Department) with synthesis of existing literature.
Objectives:
Characterize clinical presentations and imaging findings. Compare diagnostic accuracy across modalities. Analyze treatment outcomes, including procedural success rates and complications.
Tools:
Imaging: X-ray for initial screening, MRI/MSCT for soft tissue and spinal cord involvement, angiography for vascular mapping.
68 studies on the registry are indexed under Hemangioma; 11 are open to participants now.
This study's planned enrollment of 30 is below the median of 71 across 24 observational studies indexed under Hemangioma.
Browse Hemangioma studies →Assiut University is the lead sponsor of 5,078 studies on the registry; 2,178 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients with symptomatic, radiologically confirmed aggressive spinal hemangiomas treated at Assiut University Hospital. Excludes incidentally discovered cases.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Confirmed diagnosis of aggressive vertebral hemangioma via imaging (MRI/MSCT) and clinical symptoms (e.g., pain, neurological deficits).
Neurological Symptom Resolution
using the Pain intensity (VAS scale)
Time frame: 3 months
Functional Status Improvement
using ASIA Impairment Scale (primary) Threshold: ≥1-grade improvement on ASIA scale sustained for ≥3 months
Time frame: 3 months
No study locations are listed for this record.
Start is estimated for Jun 2025; primary completion for Jul 2026, 13 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.